Guardant Health (GH) Gained from Better-Than-Expected Results

Market Overview - U.S. equity markets reached new all-time highs in Q4 2025, with the S&P 500 Index rising 2.66% and the Bloomberg U.S. Aggregate Bond Index increasing by 1.10% [1] - The U.S. economy showed resilience, although consumer confidence deteriorated toward year-end, raising concerns about future spending and the labor market [1] Fund Performance - The Aristotle Growth Equity Fund (Class I-2) returned 0.95%, underperforming the Russell 1000 Growth Index's 1.12% [1] - Poor security selection in the information technology and consumer discretionary sectors detracted from performance, while positive contributions from healthcare and industrials improved relative performance [1] Company Highlight: Guardant Health, Inc. - Guardant Health, Inc. (NASDAQ:GH) was highlighted as a leading contributor to the fund's performance, driven by better-than-expected third-quarter earnings results and an acquisition of a competitor [2][3] - As of February 25, 2026, Guardant Health, Inc. stock closed at $95.27 per share, with a one-month return of -13.77% and a twelve-month gain of 126.24% [2] - The company reported approximately $281 million in revenue for Q4 2025, marking a 39% year-over-year growth [5] Hedge Fund Interest - Guardant Health, Inc. was held by 62 hedge fund portfolios at the end of Q4 2025, an increase from 50 in the previous quarter [5] - Despite its potential, the company is not listed among the 30 Most Popular Stocks Among Hedge Funds, with some analysts suggesting that certain AI stocks may offer greater upside potential and less downside risk [5]